STOCK TITAN

Atrion Reports Second Quarter 2022 Results

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Negative)
Tags

ALLEN, Texas, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ: ATRI) today announced its results for the second quarter ended June 30, 2022.

Revenues for the second quarter of 2022 totaled $48.9 million compared to $42.7 million for the same period in 2021. For the quarter ended June 30, 2022, operating income was $11.0 million, up $1.2 million over the comparable 2021 period, and net income was $9.3 million, up $424 thousand over the same period in 2021. Second quarter 2022 diluted earnings per share were $5.20 compared to $4.88 for the second quarter of 2021.

Commenting on the results for the second quarter of 2022 compared to the prior year period, David Battat, President and CEO, stated, “We had outstanding results in the just-ended quarter, with revenues up 14% and operating income up 13%, despite incurring $1.6 million in higher sales and administrative expenses. These results are particularly strong given that we continued to encounter labor and supply chain shortages, as well as localized outbreaks of COVID-19 during the quarter.” Mr. Battat continued, “Notwithstanding additional increased costs for labor, raw materials, and electricity, our gross margin improved from 42% to 43%, reflecting increases in sales of higher margin products as well as our continued focus on investing in equipment that increases quality and efficiency.”

Mr. Battat stated, “We expect double-digit growth in revenues and a 20% increase in operating income in the second half of 2022.” Mr. Battat concluded, “Cash and short and long term investments totaled $66.4 million after our purchase of 9,526 shares of the Company’s stock during the second quarter at an average price of $618.65. We remain debt free.”

Atrion Corporation develops and manufactures products primarily for medical applications. The Company’s website is www.atrioncorp.com.

Statements in this press release that are forward looking are based upon current expectations and actual results or future events may differ materially.  Such statements include, but are not limited to, the Company’s expectations regarding growth in revenues and an increase in operating income in the second half of 2022. Words such as "expects," "believes," "anticipates," "forecasts," "intends," "should", "plans," "will" and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements contained herein involve numerous risks and uncertainties, and there are a number of factors that could cause actual results or future events to differ materially, including, but not limited to, the following: the risk that the COVID-19 pandemic continues to lead to material delays and cancellations of, or reduced demand for, procedures in which our products are utilized; curtailed or delayed capital spending by hospitals and other healthcare providers; disruption to our supply chain; closures of our facilities; delays in training; delays in gathering clinical evidence; diversion of management and other resources to respond to the COVID-19 outbreak; the impact of global and regional economic and credit market conditions on healthcare spending; the risk that the COVID-19 virus continues to disrupt local economies and to cause economies in our key markets to enter prolonged recessions; changing economic, market and business conditions; acts of war or terrorism; the effects of governmental regulation; the impact of competition and new technologies; slower-than-anticipated introduction of new products or implementation of marketing strategies; implementation of new manufacturing processes or implementation of new information systems; our ability to protect our intellectual property; changes in the prices of raw materials; changes in product mix; intellectual property and product liability claims and product recalls; the ability to attract and retain qualified personnel; and the loss of, or any material reduction in sales to, any significant customers. In addition, assumptions relating to budgeting, marketing, product development and other management decisions are subjective in many respects and thus susceptible to interpretations and periodic review which may cause us to alter our marketing, capital expenditures or other budgets, which in turn may affect our results of operations and financial condition. The foregoing list of factors is not exclusive, and other factors are set forth in the Company's filings with the Securities and Exchange Commission. The forward-looking statements in this press release are made as of the date hereof, and we do not undertake any obligation, and disclaim any duty, to supplement, update or revise such statements, whether as a result of subsequent events, changed expectations or otherwise, except as required by applicable law.

Contact: Jeffery Strickland
 Vice President and Chief Financial Officer
 (972) 390-9800

ATRION CORPORATION
UNAUDITED CONSOLIDATED STATEMENTS OF INCOME
(In thousands, except per share data)

 Three Months Ended 
June 30,
 Six Months Ended 
June 30,
 2022 2021 2022 2021
Revenues$48,882  $42,693  $96,020  $81,862 
Cost of goods sold 28,049   24,826   55,943   47,656 
Gross profit 20,833   17,867   40,077   34,206 
Operating expenses 9,804   8,072   18,798   15,480 
Operating income 11,029   9,795   21,279   18,726 
        
Interest and dividend income 292   183   429   399 
Other investment income (loss) (308)  963   (548)  1,025 
Other income 60   --   85   66 
Income before income taxes 11,073   10,941   21,245   20,216 
Income tax provision (1,725)  (2,016)  (3,398)  (3,565)
Net income$9,348  $8,925  $17,847  $16,651 
        
Income per basic share$5.21  $4.89  $9.94  $9.12 
        
Weighted average basic shares outstanding 1,794   1,826   1,796   1,826 
        
        
Income per diluted share$5.20  $4.88  $9.91  $9.10 
        
Weighted average diluted shares outstanding 1,798   1,828   1,800   1,830 

ATRION CORPORATION 
CONSOLIDATED BALANCE SHEETS 
(In thousands)

 June 30, Dec. 31,
ASSETS2022 2021
 (Unaudited)  
Current assets:   
Cash and cash equivalents$16,437 $32,264
Short-term investments 34,146  29,059
Total cash and short-term investments 50,583  61,323
Accounts receivable 27,539  21,023
Inventories 54,281  50,778
Prepaid expenses and other 5,171  3,447
Total current assets 137,574  136,571


Long-term investments
 15,794  19,423
Property, plant and equipment, net 108,806  97,972
Other assets 13,143  13,298
    
 $275,317 $267,264
    
    
LIABILITIES AND STOCKHOLDERS’ EQUITY   
    
Current liabilities 19,273  13,346
Line of credit --  --
Other non-current liabilities 9,589  9,622
Stockholders’ equity 246,455  244,296
    
 $        275,317 $        267,264

 


Atrion Corp.

NASDAQ:ATRI

ATRI Rankings

ATRI Latest News

ATRI Stock Data

Surgical and Medical Instrument Manufacturing
Manufacturing
Link
Health Technology, Medical Specialties, Manufacturing, Surgical and Medical Instrument Manufacturing
US
Allentown

About ATRI

atrion corp is a medical device company located in 527 plymouth rd, plymouth, pennsylvania, united states.